AU2014227712B2 - Peptide compositions - Google Patents

Peptide compositions Download PDF

Info

Publication number
AU2014227712B2
AU2014227712B2 AU2014227712A AU2014227712A AU2014227712B2 AU 2014227712 B2 AU2014227712 B2 AU 2014227712B2 AU 2014227712 A AU2014227712 A AU 2014227712A AU 2014227712 A AU2014227712 A AU 2014227712A AU 2014227712 B2 AU2014227712 B2 AU 2014227712B2
Authority
AU
Australia
Prior art keywords
arg
cys
phe
trp
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014227712A
Other languages
English (en)
Other versions
AU2014227712A1 (en
Inventor
Bart Henderson
Shubh Sharma
Leonardus H.T. Van Der Ploeg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhythm Pharmaceuticals Inc
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of AU2014227712A1 publication Critical patent/AU2014227712A1/en
Assigned to RHYTHM PHARMACEUTICALS, INC. reassignment RHYTHM PHARMACEUTICALS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: RHYTHM METABOLIC, INC.
Application granted granted Critical
Publication of AU2014227712B2 publication Critical patent/AU2014227712B2/en
Priority to AU2018256493A priority Critical patent/AU2018256493A1/en
Priority to AU2020203353A priority patent/AU2020203353A1/en
Priority to AU2021269411A priority patent/AU2021269411A1/en
Priority to AU2024200528A priority patent/AU2024200528A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2014227712A 2013-03-15 2014-03-14 Peptide compositions Active AU2014227712B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2018256493A AU2018256493A1 (en) 2013-03-15 2018-10-30 Peptide Compositions
AU2020203353A AU2020203353A1 (en) 2013-03-15 2020-05-22 Peptide compositions
AU2021269411A AU2021269411A1 (en) 2013-03-15 2021-11-18 Peptide compositions
AU2024200528A AU2024200528A1 (en) 2013-03-15 2024-01-29 Peptide compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790469P 2013-03-15 2013-03-15
US61/790,469 2013-03-15
PCT/US2014/028590 WO2014144260A1 (en) 2013-03-15 2014-03-14 Peptide compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018256493A Division AU2018256493A1 (en) 2013-03-15 2018-10-30 Peptide Compositions

Publications (2)

Publication Number Publication Date
AU2014227712A1 AU2014227712A1 (en) 2015-10-01
AU2014227712B2 true AU2014227712B2 (en) 2018-08-02

Family

ID=50588892

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2014227712A Active AU2014227712B2 (en) 2013-03-15 2014-03-14 Peptide compositions
AU2018256493A Abandoned AU2018256493A1 (en) 2013-03-15 2018-10-30 Peptide Compositions
AU2020203353A Abandoned AU2020203353A1 (en) 2013-03-15 2020-05-22 Peptide compositions
AU2021269411A Abandoned AU2021269411A1 (en) 2013-03-15 2021-11-18 Peptide compositions
AU2024200528A Pending AU2024200528A1 (en) 2013-03-15 2024-01-29 Peptide compositions

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2018256493A Abandoned AU2018256493A1 (en) 2013-03-15 2018-10-30 Peptide Compositions
AU2020203353A Abandoned AU2020203353A1 (en) 2013-03-15 2020-05-22 Peptide compositions
AU2021269411A Abandoned AU2021269411A1 (en) 2013-03-15 2021-11-18 Peptide compositions
AU2024200528A Pending AU2024200528A1 (en) 2013-03-15 2024-01-29 Peptide compositions

Country Status (11)

Country Link
US (3) US10196425B2 (de)
EP (2) EP2970388B1 (de)
JP (3) JP6622690B2 (de)
CN (1) CN105492456A (de)
AU (5) AU2014227712B2 (de)
CA (1) CA2906694A1 (de)
ES (1) ES2693761T3 (de)
HK (1) HK1220697A1 (de)
RU (2) RU2020120797A (de)
TR (1) TR201815173T4 (de)
WO (1) WO2014144260A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
TR201815173T4 (tr) 2013-03-15 2018-11-21 Rhythm Pharmaceuticals Inc Peptit bileşimleri.
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
EP3356386B1 (de) 2015-09-30 2024-02-14 Rhythm Pharmaceuticals, Inc. Verfahren zur behandlung von melanocortin-4-rezeptorweg-assoziierten erkrankungen
AU2017340816C1 (en) * 2016-10-04 2022-02-10 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
WO2018167194A1 (en) * 2017-03-15 2018-09-20 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
EP3773897A1 (de) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Zusammensetzungen zur behandlung von nierenkrankheit
WO2020053414A1 (en) * 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
CN113209270B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备防治急性肝衰竭药物中的应用
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
CN116789802A (zh) * 2023-06-25 2023-09-22 湖北省农业科学院畜牧兽医研究所 一种山羊mc4r增强型突变体及其应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292291A2 (de) * 1987-05-22 1988-11-23 University Patents, Inc. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
WO2000035952A2 (en) * 1998-12-14 2000-06-22 Melacure Therapeutics Ab Compounds for control of eating, growth and body weight
WO2002018437A2 (en) * 2000-08-30 2002-03-07 F. Hoffmann-La Roche Ag Cyclic peptides having melanocortin-4 receptor agonist activity
WO2003006620A2 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
WO2005000339A2 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
WO2005014617A2 (en) * 2003-08-08 2005-02-17 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
WO2007008704A2 (en) * 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Melanocortin receptor ligands
WO2008147556A2 (en) * 2007-05-25 2008-12-04 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
WO2009151383A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
WO2010144344A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
WO2010144038A1 (en) * 2009-06-08 2010-12-16 Astrazeneca Ab Melanocortin receptor-specific peptides
WO2011017209A1 (en) * 2009-08-05 2011-02-10 Ipsen Pharma S.A.S. Use of melanocortins to treat dyslipidemia
WO2011060355A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US8343031B2 (en) * 2004-03-23 2013-01-01 Michael Gertner Obesity treatment systems
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
EP1915168A4 (de) 2005-07-08 2010-03-31 Ipsen Pharma Liganden von melanocortin-rezeptoren
TW200848424A (en) 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
ES2690556T3 (es) 2007-11-05 2018-11-21 Ipsen Pharma S.A.S. Uso de melanocortinas para tratar la sensibilidad a la insulina
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
UA114088C2 (xx) 2011-06-14 2017-04-25 Лікарська композиція з пролонгованим вивільненням для ін'єкцій
EP2705835A1 (de) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Wässrige gelbildende Zusammensetzungen aus löslichen aktiven pharmazeutischen Peptiden, die eine modifizierte Freisetzung ermöglichen
JP6538025B2 (ja) * 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
TR201815173T4 (tr) 2013-03-15 2018-11-21 Rhythm Pharmaceuticals Inc Peptit bileşimleri.

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292291A2 (de) * 1987-05-22 1988-11-23 University Patents, Inc. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
WO2000035952A2 (en) * 1998-12-14 2000-06-22 Melacure Therapeutics Ab Compounds for control of eating, growth and body weight
WO2002018437A2 (en) * 2000-08-30 2002-03-07 F. Hoffmann-La Roche Ag Cyclic peptides having melanocortin-4 receptor agonist activity
WO2003006620A2 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
WO2005000339A2 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
WO2005014617A2 (en) * 2003-08-08 2005-02-17 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
WO2007008704A2 (en) * 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Melanocortin receptor ligands
WO2008147556A2 (en) * 2007-05-25 2008-12-04 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
WO2009151383A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
WO2010144344A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
WO2010144038A1 (en) * 2009-06-08 2010-12-16 Astrazeneca Ab Melanocortin receptor-specific peptides
WO2011017209A1 (en) * 2009-08-05 2011-02-10 Ipsen Pharma S.A.S. Use of melanocortins to treat dyslipidemia
WO2011060355A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Al-Obeidi F. et al. "Potent and Prolonged Acting Cyclic Lactam Analogues of a-Melanotropin: DesignBased on Molecular Dynamics" J. Med. Chem. (1989) 32: 2555-2561 *
Bednarek M.A. et al. "Structure-function studies on the cyclic peptide MT-II, lactamderivative of a-melanotropin" Peptides (1999) 20: 401-409 *
Bednarek M.A. et al., Biochemical and Biophysical Research Communications (1999) 261: 209–213 *
Grieco P. et al. "Further structure-activity studies of lactam derivatives of MT-II and SHU-9119: Their activity and selectivity at human melanocortin receptors 3, 4, and 5" Peptides (2007) 28: 1191-1196 *
Grieco P. et al. "Structure-Activity Studies of the Melanocortin Peptides: Discovery of Potentand Selective Affinity Antagonists for the hMC3 and hMC4 Receptors" J. Med. Chem. (2002) 45: 5287-5294 *
Kontijevskis A. et al. "Proteochemometric analysis of small cyclic peptides' interaction with wild-type and chimeric melanocortin receptors" Proteins (2007) 69(1): 83-96 *
Yan L.Z. et al. "Potent and selective MC-4 receptor agonists based on a novel disulfide scaffold" Bioorganic & Medicinal Chemistry Letters (2005) 15: 4611-4614 *

Also Published As

Publication number Publication date
RU2725150C2 (ru) 2020-06-30
US20190092815A1 (en) 2019-03-28
US10196425B2 (en) 2019-02-05
EP3450449A2 (de) 2019-03-06
JP7046871B2 (ja) 2022-04-04
EP2970388B1 (de) 2018-07-25
TR201815173T4 (tr) 2018-11-21
AU2021269411A1 (en) 2021-12-16
JP2022084844A (ja) 2022-06-07
WO2014144260A1 (en) 2014-09-18
AU2018256493A1 (en) 2018-11-22
EP2970388A1 (de) 2016-01-20
AU2020203353A1 (en) 2020-06-11
ES2693761T3 (es) 2018-12-13
RU2015145593A (ru) 2017-04-24
US20210040155A1 (en) 2021-02-11
CN105492456A (zh) 2016-04-13
RU2020120797A (ru) 2020-07-02
JP2016516719A (ja) 2016-06-09
US20160017001A1 (en) 2016-01-21
CA2906694A1 (en) 2014-09-18
EP3450449A3 (de) 2019-06-12
JP6622690B2 (ja) 2019-12-18
US10858399B2 (en) 2020-12-08
AU2024200528A1 (en) 2024-02-15
AU2014227712A1 (en) 2015-10-01
JP2019172693A (ja) 2019-10-10
HK1220697A1 (zh) 2017-05-12

Similar Documents

Publication Publication Date Title
US10858399B2 (en) Peptide compositions
AU2019200101B2 (en) Pharmaceutical Compositions
EP3356386B1 (de) Verfahren zur behandlung von melanocortin-4-rezeptorweg-assoziierten erkrankungen
Rivier et al. Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance
CA2620577A1 (en) Peptide mimics of melanocyte stimulating hormone
CN118240012A (zh) 肽组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)